يعرض 1 - 10 نتائج من 50 نتيجة بحث عن '"Andrew Foxley"', وقت الاستعلام: 1.59s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Using qualitative interviews to identify patient-reported clinical trial endpoints and analyses that are the most meaningful to patients with advanced breast cancer.

    المؤلفون: Emuella Flood, Anna Krasnow, Cecilia Orbegoso, Stella Karantzoulis, Julie Bailey, Solène Bayet, Arthur Elghouayel, Andrew Foxley, Roberto Sommavilla, Gaia Schiavon

    المصدر: PLoS ONE, Vol 18, Iss 1, p e0280259 (2023)

    مصطلحات موضوعية: Medicine, Science

    وصف الملف: electronic resource

    Relation: https://doaj.org/toc/1932-6203

    URL الوصول: https://doaj.org/article/5be0cc54212f40018a545151da002e00

    Find this article in full text from ProQuest Full Text Finder
    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer

    المؤلفون: Lillian M. Smyth, Gerald Batist, Funda Meric-Bernstam, Peter Kabos, Iben Spanggaard, Ana Lluch, Komal Jhaveri, Andrea Varga, Andrea Wong, Alison M. Schram, Helen Ambrose, T. Hedley Carr, Elza C. de Bruin, Carolina Salinas-Souza, Andrew Foxley, Joana Hauser, Justin P. O. Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta, Myria Nikolaou, Gaia Schiavon, Pedram Razavi, Udai Banerji, José Baselga, David M. Hyman, Sarat Chandarlapaty

    المصدر: npj Breast Cancer, Vol 7, Iss 1, Pp 1-7 (2021)

    مصطلحات موضوعية: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

    وصف الملف: electronic resource

    Relation: https://doaj.org/toc/2374-4677

    URL الوصول: https://doaj.org/article/97cb292e26054c75a968bad21fc37c9b

    Find this article in full text from ProQuest Full Text Finder
    أضف إلى المفضلة
  3. 3
    Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

    المؤلفون: Nicholas C. Turner, Mafalda Oliveira, Sacha J. Howell, Florence Dalenc, Javier Cortes, Henry L. Gomez Moreno, Xichun Hu, Komal Jhaveri, Petr Krivorotko, Sibylle Loibl, Serafin Morales Murillo, Meena Okera, Yeon Hee Park, Joohyuk Sohn, Masakazu Toi, Eriko Tokunaga, Samih Yousef, Lyudmila Zhukova, Elza C. de Bruin, Lynda Grinsted, Gaia Schiavon, Andrew Foxley, Hope S. Rugo

    المصدر: New England Journal of Medicine. 388:2058-2070

    مصطلحات موضوعية: General Medicine

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::dfd11470d58e0668b288ffbfb9d29818
    https://doi.org/10.1056/nejmoa2214131

    Find this article in full text from ProQuest
    أضف إلى المفضلة
  4. 4
    Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial

    المؤلفون: Sacha J Howell, Angela Casbard, Margherita Carucci, Kate Ingarfield, Rachel Butler, Sian Morgan, Magdalena Meissner, Catherine Bale, Pavel Bezecny, Sarah Moon, Chris Twelves, Ramachandran Venkitaraman, Simon Waters, Elza C de Bruin, Gaia Schiavon, Andrew Foxley, Robert H Jones

    المصدر: Howell, S J, Casbard, A, Carucci, M, Ingarfield, K, Butler, R, Morgan, S, Meissner, M, Bale, C, Bezecny, P, Moon, S, Twelves, C, Venkitaraman, R, Waters, S, de Bruin, E C, Schiavon, G, Foxley, A & Jones, R H 2022, ' Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION) : overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial ', The Lancet. Oncology, vol. 23, no. 7, pp. 851-864 . https://doi.org/10.1016/S1470-2045(22)00284-4

    مصطلحات موضوعية: Adult, Phosphatidylinositol 3-Kinases/genetics, Adolescent, Receptor, ErbB-2, Receptor, ErbB-2/metabolism, Breast Neoplasms, Phosphatidylinositol 3-Kinases, Breast Neoplasms/drug therapy, Double-Blind Method, Antineoplastic Combined Chemotherapy Protocols, Humans, Pyrroles, Neoplasm Recurrence, Local/pathology, Fulvestrant, Manchester Cancer Research Centre, Aromatase Inhibitors, Antineoplastic Combined Chemotherapy Protocols/adverse effects, ResearchInstitutes_Networks_Beacons/mcrc, Progression-Free Survival, Pyrimidines, Receptors, Estrogen, Oncology, Female, Receptors, Estrogen/metabolism, Neoplasm Recurrence, Local, Proto-Oncogene Proteins c-akt, Aromatase Inhibitors/therapeutic use

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b8b7c1cc7c7d91a6ed98ec5f578778f
    https://doi.org/10.1016/s1470-2045(22)00284-4

    View record from ScienceDirect Find this article in full text from ProQuest Full Text via ClinicalKey
    أضف إلى المفضلة
  5. 5
    Data from Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers

    المؤلفون: Johann S. de Bono, Yvette Drew, Juanita S. Lopez, Bristi Basu, Ruth Plummer, Udai Banerji, Christopher J. Lord, Andrew Foxley, Justin P.O. Lindemann, Paul Rugman, Emma Hall, Laura Finneran, Karen E. Swales, Shaun Decordova, Florence I. Raynaud, Ruth Ruddle, Nicholas C. Turner, Heidrun Gevensleben, Neha Chopra, Nina Tunariu, Alison Turner, Mona Parmar, Ruth Matthews, Sarah Ward, Daniel Nava Rodrigues, Ines Figueiredo, Susana Miranda, Ruth Riisnaes, Rowan Miller, Desamparados Roda, Suzanne Carreira, Joline S.J. Lim, Stephen J. Pettitt, Vasiliki Michalarea, Rebecca Kristeleit, Timothy A. Yap

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::01e33adbfd1faf3496d00cefbd4e1d17
    https://doi.org/10.1158/2159-8290.c.6547955.v1

    أضف إلى المفضلة
  6. 6
    Supplementary Data from Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers

    المؤلفون: Johann S. de Bono, Yvette Drew, Juanita S. Lopez, Bristi Basu, Ruth Plummer, Udai Banerji, Christopher J. Lord, Andrew Foxley, Justin P.O. Lindemann, Paul Rugman, Emma Hall, Laura Finneran, Karen E. Swales, Shaun Decordova, Florence I. Raynaud, Ruth Ruddle, Nicholas C. Turner, Heidrun Gevensleben, Neha Chopra, Nina Tunariu, Alison Turner, Mona Parmar, Ruth Matthews, Sarah Ward, Daniel Nava Rodrigues, Ines Figueiredo, Susana Miranda, Ruth Riisnaes, Rowan Miller, Desamparados Roda, Suzanne Carreira, Joline S.J. Lim, Stephen J. Pettitt, Vasiliki Michalarea, Rebecca Kristeleit, Timothy A. Yap

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75b42dc1c2ce5b8015019651ef216b42
    https://doi.org/10.1158/2159-8290.22535825

    أضف إلى المفضلة
  7. 7
    Supplementary Figure 1 from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

    المؤلفون: David M. Hyman, José Baselga, Sarat Chandarlapaty, Barry S. Taylor, Maurizio Scaltriti, Udai Banerji, Gaia Schiavon, Vicky Rowlands, Martin Pass, Michele Moschetta, Robert McEwen, Rhiannon Maudsley, Justin P.O. Lindemann, Joana Hauser, Andrew Foxley, Elza C. de Bruin, Claire Corcoran, Des D. Cashell, Alan Barnicle, Jack Ashton, Helen J. Ambrose, Laura Biganzoli, Marie-Paule Sablin, Ingrid A. Mayer, Eva M. Ciruelos, Mafalda Oliveira, Kenji Tamura, Lillian M. Smyth

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4f3ddb7682626f66115790cb0108aba
    https://doi.org/10.1158/1078-0432.22476300.v1

    أضف إلى المفضلة
  8. 8
    Data from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

    المؤلفون: David M. Hyman, José Baselga, Sarat Chandarlapaty, Barry S. Taylor, Maurizio Scaltriti, Udai Banerji, Gaia Schiavon, Vicky Rowlands, Martin Pass, Michele Moschetta, Robert McEwen, Rhiannon Maudsley, Justin P.O. Lindemann, Joana Hauser, Andrew Foxley, Elza C. de Bruin, Claire Corcoran, Des D. Cashell, Alan Barnicle, Jack Ashton, Helen J. Ambrose, Laura Biganzoli, Marie-Paule Sablin, Ingrid A. Mayer, Eva M. Ciruelos, Mafalda Oliveira, Kenji Tamura, Lillian M. Smyth

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28c1b1cc28095071714876d36a725e47
    https://doi.org/10.1158/1078-0432.c.6529365.v1

    أضف إلى المفضلة
  9. 9
    Data from Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)

    المؤلفون: Julia M.W. Gee, Andrew Foxley, Pauline Finlay, Rahul Deb, Gaia Schiavon, Paul Rugman, Martin Pass, Justin P.O. Lindemann, Loumpiana Koulai, Elza C. de Bruin, Marie Cullberg, S.Y. Amy Cheung, Roberta Littleford, Petra Rauchhaus, Kieran Horgan, Ali Jahan, Samreen Ahmed, Daniel Rea, Anthony Skene, Chris Holcombe, Abigail Evans, Kwok-Leung Cheung, Robert E. Coleman, John F.R. Robertson

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36ce4aaa6b32841a0165d4e23b5bbbdf
    https://doi.org/10.1158/1078-0432.c.6530157.v1

    أضف إلى المفضلة
  10. 10
    Supplementary Figure 3 from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

    المؤلفون: David M. Hyman, José Baselga, Sarat Chandarlapaty, Barry S. Taylor, Maurizio Scaltriti, Udai Banerji, Gaia Schiavon, Vicky Rowlands, Martin Pass, Michele Moschetta, Robert McEwen, Rhiannon Maudsley, Justin P.O. Lindemann, Joana Hauser, Andrew Foxley, Elza C. de Bruin, Claire Corcoran, Des D. Cashell, Alan Barnicle, Jack Ashton, Helen J. Ambrose, Laura Biganzoli, Marie-Paule Sablin, Ingrid A. Mayer, Eva M. Ciruelos, Mafalda Oliveira, Kenji Tamura, Lillian M. Smyth

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cc68c5e9ff3cae038afb89d5bd3f604
    https://doi.org/10.1158/1078-0432.22476294

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء